08 April 2021>: Articles
A 58-Year-Old Woman with Acute Gastric Perforation Due to Metastatic Ductal Carcinoma 18 Years Following Bilateral Mastectomy for Invasive Ductal Carcinoma of the Breast
Unusual clinical course, Challenging differential diagnosis, Diagnostic / therapeutic accidents, Unusual setting of medical care, Educational Purpose (only if useful for a systematic review or synthesis)
William A. Nehmeh A* , Joseph Derienne A , Léa El Khoury B , Serge Kassar B , Viviane Trak-Smayra B , Roger Noun A , Ghassan Chakhtoura ADOI: 10.12659/AJCR.927094
Am J Case Rep 2021; 22:e927094
Table 1. Characteristics of gastric metastasis of breast cancer: Cases in the literature since 2005.
Authors | Year | Number of cases | Age [range] (years) | Histological type | ER | PR | HER2 |
---|---|---|---|---|---|---|---|
Akcali et al []11 | 2005 | 1 | 50 | IDL | NA | NA | NA |
Kudo et al []12 | 2005 | 1 | 59 | NA | NA | NA | NA |
Whitty et al []13 | 2005 | 1 | 55 | IDC | + | + | NA |
Jones et al []14 | 2007 | 2 | 5161 | ILCILC | ++ | ++ | −NA |
Dumoulin et al []15 | 2009 | 1 | 60 | ILC | + | + | − |
Pectasides et al []16 | 2009 | 8 | 4452636758617549 | ILCIDC ILC ILCIDC ILCILCILC | NA NANANANANA NA NA | NANANANANANA NANA | NANA NANANANANANA |
Vennapusa et al []17 | 2010 | 1 | 61 | ILC | + | + | NA |
Yamamoto et al []18 | 2010 | 1 | 80 | IDC | − | − | NA |
Almubarak et al []8 | 2011 | 35 | 55 [37−74] | 34 ILC1 IDC | 19+2−1+1− | 19+2−1+1− | 19−2−1+1+ |
Koike et al []20 | 2011 | 3 | 425454 | ILCILCIDC | +++ | +++ | −−− |
Abid et al []21 | 2013 | 1 | 59 | ILC | + | + | − |
Loubna et al []22 | 2013 | 2 | 7050 | IDCIDC | −− | −− | NA+ |
Hild et al []23 | 2014 | 1 | 53 | ILC | + | + | − |
Eren et al []24 | 2014 | 1 | 37 | ILC | + | + | NA |
Waseda et al []25 | 2015 | 1 | 57 | ILC | + | + | NA |
Buka et al []26 | 2016 | 1 | 58 | ILC | + | + | − |
El Hage et al []27 | 2016 | 5 | 4266587570 | ILCILCILCILCILC | +++++ | +−+++ | −−+−− |
Wong et al []28 | 2016 | 1 | 72 | ILC | + | + | − |
Rodrigues et al []29 | 2016 | 12 | [40−86] | 5 ILC7 IDC | +11/12 | + 6/9 | + 2/3 |
Yim et al []30 | 2017 | 1 | 65 | ILC | − | − | + |
Barranco et al []31 | 2017 | 1 | 48 | IDC | + | − | NA |
Gurzu et al []32 | 2018 | 2 | 6873 | ILCIDC | +− | −− | NA+ |
Woo et al []33 | 2018 | 1 | 51 | ILC | + | + | − |
De Gruttola et al []10 | 2019 | 1 | 61 | ILC | + | + | − |
D2 – D2 lymphadenectomy; ER – estrogen receptor; GM – gastric metastasis; HER2 – human epidermal growth factor receptor; IDC – invasive ductal carcinoma; ILC – invasive lobular carcinoma; MS – mean survival; NA – not available; PR – progesterone receptor; STG – subtotal gastrectomy; TG – total gastrectomy. | |||||||
Authors | pTNM | Interval to GM [range] (months) | Perforated | Treatment for gastric metastasis | Other metastasis | Survival (months) | |
Akcali et al []11 | T2N0M0 | 108 | No | TG+ chemotherapy | No | Alive at 41 | |
Kudo et al []12 | NA | 48 | No | Endoscopic resection | No | Alive at 24 | |
Whitty et al []13 | T2N0M0 | 131 | No | TG+ Total colectomy | No | NA | |
Jones et al []14 | T2T3N1 | 36168 | NoNo | TG + D2Chemotherapy | BoneBone, brain | Palliative careNA | |
Dumoulin et al []15 | pT1cN1M0 | 120 | No | Diagnostic laparoscopy | Peritoneal carcinosis | Palliative care | |
Pectasides et al []16 | NANANANANANANANA | 351855238508244 | NoNoNoNoNoNoNoNo | Chemotherapy for all | Ovaries, boneBone, lungNoNoSkin, lung, bonePeritoneum, boneBoneNo | Dead after 11Dead after 23Alive at 9Alive at 44Dead after 4Dead after 9Dead after 1Alive at 39 | |
Vennapusa et al []17 | T2N1M1 | 0 | No | Chemotherapy | Ribs, vertebrae, orbit | NA | |
Yamamoto et al []18 | pT2N2M0 | 6 | No | Chemotherapy | Brain | Alive at 12 | |
Almubarak et al []8 | 9T115T28T33T4 | 57 [0–230] | No | 4 TG3 Bypass26 Chemotherapy2 Hormonotherapy | 20: Bone, liver, peritoneum, skin, colorectal, esophagus | 53% overall 24 months survival | |
Koike et al []20 | NANANA | NANANA | NoNoNo | ChemotherapyChemotherapyChemotherapy | NoBoneBone | Alive at 56Dead after 58Dead after 27 | |
Abid et al []21 | T1N1M1 | 0 | No | Chemotherapy | Colon | NA | |
Loubna et al []22 | T4N2M0pT1cN0M0 | 1260 | NoNo | ChemotherapySurgery | NoNo | Dead after 3Alive at 18 | |
Hild et al []23 | T3N2 | 84 | No | Chemotherapy | No | Alive at 30 | |
Eren et al []24 | NA | 72 | No | Chemotherapy | NA | Dead after 3 | |
Waseda et al []25 | NA | 60 | No | Chemotherapy | Liver | NA | |
Buka et al []26 | NA | −14 | No | TG + D2 | Colorectal | Dead after 86 | |
El Hage et al []27 | T3N2M1T1bN1M1T2N2M0T2NxM1T2N3M1 | 06840218 | NoNoNoNoNo | Chemotherapy for all | NoYesYesYesYes | NADead after 11Dead after 13Dead after 1Dead after 19 | |
Wong et al []28 | pT2N0M0 | 48 | Yes | Laparotomy for perforated ulcer | No | Alive at 12 | |
Rodrigues et al []29 | NA | [0–156] | No | 8 chemotherapy4 surgery: 3 TG +D21 STG +D2 | 10/12: 9 Bone3 Lungs 1 Large bowel 1 liver 1 skin 2 esophagus 1 mediastinum | MS: 14.58MS 4 surgical cases: 38 | |
Yim et al []30 | pT2N3M0 | 48 | No | Chemotherapy | Bone | NA | |
Barranco et al []31 | NA | 0 | Yes | None | NA | Instant death | |
Gurzu et al []32 | NANA | 024 | YesNo | TG + D1STG + D1 | NANA | Dead after 2Alive at 4 | |
Woo et al []33 | pT3N3M1 | 12 | No | STG with Bilroth II+ D2 | Bone, ovary, bone marrow, omentum | Alive at 66 | |
De Gruttola et al []10 | T3N0M0 | 96 | Yes | TG + Hormonotherapy | No | Alive at 6 | |
D2 – D2 lymphadenectomy; ER – estrogen receptor; GM – gastric metastasis; HER2 – human epidermal growth factor receptor; IDC – invasive ductal carcinoma; ILC – invasive lobular carcinoma; MS – mean survival; NA – not available; PR – progesterone receptor; STG – subtotal gastrectomy; TG – total gastrectomy. |